# Tenax Therapeutics, Inc. (TENX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TENX
## Company Profile
- Ticker: TENX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.72 USD
- Market cap: 290450491.04999995 USD
- Last updated: 2026-08-12
## Business Overview
### Phase 3 Cardiopulmonary Developer
Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary disease. Its strategy is centered on levosimendan, a K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF.
### Lead Program: TNX-103
TNX-103 is the oral formulation of levosimendan and is being evaluated in two pivotal Phase 3 trials, LEVEL and LEVEL-2. The program is designed for a disease setting with no approved therapy, giving Tenax a focused development path in a high-need cardiopulmonary population.
### Clinical Rationale
Levosimendan has prior global experience as an intravenous therapy for acutely decompensated heart failure outside the U.S. and Canada. Tenax's Phase 2 HELP trial and open-label extension supported the potential for IV TNX-101 and oral TNX-103 to improve exercise capacity, quality of life, and other clinical assessments in PH-HFpEF.
### Strategic Position
Tenax is best understood as a single-asset, late-stage cardiopulmonary company. Its value is tightly linked to whether oral levosimendan can establish clinically meaningful benefit in PH-HFpEF and support a regulatory path in a market with no approved product.
## Why The Stock Is Moving

As of Aug 12, 2026, TENX closed up 6.17% at $1.72. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline data from the Phase 3 LEVEL trial expected in August 2026.
- LEVEL results presentation planned for ESC Congress 2026.
- Expected LEVEL-2 enrollment completion by the end of 2027.

## Recent News
- 2026-08-10 11:00 EST — [Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF](https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-topline-results-from-phase-3-level-clinical-trial-o-946ce9d6) — Source: Tenax Therapeutics, Inc.
- 2026-07-31 11:00 EST — [Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-e8377bbc) — Source: Tenax Therapeutics, Inc.
- 2026-07-02 20:05 EST — [Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--795d95d7) — Source: Tenax Therapeutics, Inc.
- 2026-07-02 11:00 EST — [Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026](https://biopharmsignal.com/news/TENX/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial--99fd99ae) — Source: Tenax Therapeutics, Inc.
- 2026-05-12 11:00 EST — [Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TENX/tenax-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-c6147cfe) — Source: Tenax Therapeutics, Inc.